DNA Repair in Cancer Therapy

• Author : Lawrence C. Panasci,Moulay A. Alaoui-Jamali
• Publisher : Humana
• Release : 19 November 2010

A comprehensive review of the recent developments in DNA repair that have potential for translational and clinical applications. The authors explain in detail the various mechanisms by which cancer cells can circumvent anticancer therapy and limits its usefulness in patients. They also review the clinical impact of such novel inhibitors of DNA repair mechanisms as methylguanine-DNA-methyltransferase. Also examined are inhibitors of other DNA repair enzymes such as PARP and DNA-PK, now under development and close to clinical trials. The book

• Author : John Pollard,Nicola Curtin
• Publisher : Humana
• Release : 21 December 2018

Over the past decade a complex role for DNA damage response (DDR) in tumorigenesis has emerged. A proficient DDR has been shown to be a primary cause for cellular resistance to the very many DNA damaging drugs, and IR, that are widely used as standard-of-care across multiple cancer types. It has also been shown that defects in this network, predominantly within the ATM mediated signaling pathway, are commonly observed in cancers and may be a primary event during tumorigenesis. Such

• Author : José Díaz-Chávez,Rosa Maria Bermudez-Cruz,David Y. Lee
• Publisher : Frontiers Media SA
• Release : 29 April 2022

• Author : Timothy A. Yap,Geoffrey I. Shapiro
• Publisher : Springer
• Release : 11 September 2023

This book discusses the latest developments in Poly (ADP-ribose) polymerase (PARP) inhibitor drug development. It focuses on the translational and clinical development of the latest drugs, as well as the evidence for regulatory approval of PARP inhibitors in multiple different molecular subtypes and tumor indications. The most-up-to-date information on basic scientific research on DNA repair pathways and the DNA Damage Response (DDR) is also covered. Every chapter contains insight into the preclinical, translational along with clinical aspects of a specific

• Author : Amila Suraweera,James A. L. Brown,Martin Francis Lavin,Yi Chieh Lim
• Publisher : Frontiers Media SA
• Release : 10 March 2022

• Author : Mehmet Gunduz
• Publisher : BoD – Books on Demand
• Release : 25 March 2015

Cancer is one of the leading causes of death in most countries and its consequences result in huge economic, social and psychological burden. Breast cancer is the most frequently diagnosed cancer type and the leading cause of cancer death among females. In this book, we discussed gene expression and DNA abnormalities including methylation in breast cancer. A recent important topic, roles of miRNAs and their potential use in cancer therapy have been discussed in this cancer type as well. Bioinformatics

• Author : Nicola J. Curtin,Ricky A. Sharma
• Publisher : Unknown
• Release : 05 June 2023

PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP--poly ADP ribose polymerase--in cancer therapy. The volume covers the history of the discovery of PARP and its role in DNA repair. Additionally, it describes the discovery of the PARP family, and includes a discussion of other DNA maintenance-associated PARPs. As well, the volume features a section on the accessible chemistry behind the development of inhibitors. PARP inhibitors--PARPi--are a group of pharmacological inhibitors that are particularly good

• Author : Katy S. Orr
• Publisher : Unknown
• Release : 05 June 2023

The BRCA1 and BRCA2 Breast and Ovarian Cancer Susceptibility Genes - Implications for DNA Damage Response, DNA Repair and Cancer Therapy.

• Author : Mark R. Kelley
• Publisher : Academic Press
• Release : 12 September 2011

Mark R. Kelley

• Author : Oreekha Amin
• Publisher : Unknown
• Release : 05 June 2023

" Pelvic epithelial cancer (usually referred to as ovarian cancer) represents one-fourth of the malignancies of the female genital tract. Women carrying Breast Cancer Antigen (BRCA) germline mutations are at increased risk to develop pelvic epithelial cancer, and up to 50% of all patients with pelvic epithelial cancer show functional impairment of BRCA1 [1]. These mutations in BRCA1/2 genes exhibit impaired ability to repair double-stranded DNA breaks via homologous recombination (HR). Moreover, BRCA1 mutated cancer cells were found to have over-expression of Insulin

• Author : John Mendelsohn,Peter M. Howley,Mark A. Israel,Joe W. Gray,Craig B. Thompson
• Publisher : Elsevier Health Sciences
• Release : 04 January 2014

Stay current with the latest discoveries in molecular and genomic research. Sweeping revisions throughout include eight brand-new chapters on: Tumor Suppressor Genes; Inflammation and Cancer; Cancer Systems Biology: The Future; Biomarkers Assessing Risk of Cancer; Understanding and Using Information About Cancer Genomes; The Technology of Analyzing Nucleic Acids in Cancer; Molecular Abnormalities in Kidney Cancer; and Molecular Pathology.

• Author : Lawrence C. Panasci,Moulay A. Alaoui-Jamali
• Publisher : Springer Science & Business Media
• Release : 19 March 2004

A comprehensive review of the recent developments in DNA repair that have potential for translational and clinical applications. The authors explain in detail the various mechanisms by which cancer cells can circumvent anticancer therapy and limits its usefulness in patients. They also review the clinical impact of such novel inhibitors of DNA repair mechanisms as methylguanine-DNA-methyltransferase. Also examined are inhibitors of other DNA repair enzymes such as PARP and DNA-PK, now under development and close to clinical trials. The book

• Author : Lawrence Panasci,Raquel Aloyz,Moulay Alaoui-Jamali
• Publisher : Springer Science & Business Media
• Release : 09 December 2012

​A comprehensive review of the recent developments in DNA repair research that have potential for translational applications. The book explains in detail the various biological mechanisms by which cancer cells can circumvent anticancer therapy and limits its usefulness in patients. They also review the impact of such novel inhibitors of DNA repair mechanisms as methylguanine-DNA-methyltransferase. Also examined are inhibitors of other DNA repair enzymes such as PARP and DNA-PK. The book captures-for both cancer researchers and oncologists dealing with hallmark "

• Author : Satoshi Kokura,Toshikazu Yoshikawa,Takeo Ohnishi
• Publisher : Springer
• Release : 07 June 2016

This comprehensive work broadens readers' understanding of the rudimentary mechanism of the anti-cancer effect of hyperthermia. It also presents state-of-the-art clinical outcomes by hyperthermia treatment of cancer. In the past few decades, basic and clinical research have shown through in vitro experiments that hyperthermia inhibits epithelial-mesenchymal transition (EMT), resulting in the prevention of metastasis. It also has been learned that hyperthermia shows its superior benefit when applied in combination with radiation therapy, chemotherapy, or various immunotherapies as treatments of several

• Author : Pierre Hainaut,Klas G. Wiman
• Publisher : Springer Science & Business Media
• Release : 05 October 2007

p53 has emerged as a key tumor suppressor and important target for novel cancer therapy. This book, written by world-leading p53 researchers including many of those who have shaped the field over the past 25 years, provides unique insights into the progress of the field and the prospects for better cancer diagnosis and therapy in the future.